| Range |
75 to 80 Hormone receptor-positive: 15 to 20 ERBB2-positive %
|
| Organism |
Human Homo sapiens |
| Reference |
Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol. 2007 Mar8(3):235-44. p.235 left column bottom paragraphPubMed ID17329194
|
| Primary Source |
Konecny G et al., Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst. 2003 Jan 15 95(2):142-53 AND Slamon DJ et al., Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989 May 12 244(4905):707-12.PubMed ID12529347, 2470152
|
| Comments |
About half of ERBB2-positive cases coexpress hormone
receptors. The remaining 10–15% of breast cancers are in
a so-called receptor-negative or triple-negative category, as
defined by absent expression of these three proteins. |
| Entered by |
Uri M |
| ID |
106093 |